P1.084. Exploring the Role of Adjuvant Nivolumab After Neoadjuvant FLOT Followed by Surgery in Resectable ESCC: Implications for Cisplatin-Unfit Patients

Clicks: 19
ID: 326005
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Steady

Ranked #241 of 453 articles by views in diseases of the esophagus : official journal of the international society for diseases of the esophagus

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 453 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Topic Esophageal Cancer: Adjuvant and Neo-Adjuvant Therapies Background In Western countries, neoadjuvant chemoradiotherapy (CRT) is standard, and CheckMate 577 showed adjuvant nivolumab prolonged disease free survival (DFS) with non-pathological complete response (non-pCR). In Japan, DCF is standard based on JCOG1109. For cisplatin-unfit patients, FLOT may be an alternative option but adjuvant nivolumab remains unclear in this population. Methods We retrospectively analyzed patients with resectable locally advanced esophageal squamous cell carcinoma who received neoadjuvant FLOT between November 2022 and September 2025 at our institution and achieved R0 resection with non-pCR. DFS and overall survival (OS) were evaluated to assess the efficacy and the safety of adjuvant nivolumab compared to observation group. Results A total of 50 patients were analyzed: 37 (74%) underwent observation and 13 (26%) received adjuvant nivolumab. Median follow-up was 16.4 vs 11.5 months. Median age was 79 vs 78 years, and males comprised 75.7% vs 76.9%. Postoperative performance status (0/1/2) was 56.8/40.5/2.7% vs 61.5/30.8/7.7%. Pathological ypStage (I/II/III/IVB) was 35.1/35.1/27.0/2.7% vs 15.4/30.8/30.8/53.8%. pT0/1/2/3 was 5.4/48.6/10.8/32.4% vs 0/23.0/23.0/53.8%, and pN0/1/2/3 was 48.6/27.0/16.2/8.1% vs 30.8/46.2/15.4/7.7%. Lymph node positivity was significantly higher in the nivolumab group (p=0.01), with a trend toward more ypT3 disease (p=0.07). Median DFS and OS were not reached. One-year DFS was 80.7% vs 80.8% (HR 1.61, 95%CI 0.41–6.36), and one-year OS was 89.9% vs 80.0% (HR 0.80, 95%CI 0.09–7.03). Immune-related adverse events included Grade 3 pneumonitis (n=1), Grade 2 adrenal insufficiency (n=2), and Grade 1 dermatitis (n=1), all manageable without treatment-related deaths. Conclusion In patients with resectable locally advanced ESCC who underwent neoadjuvant FLOT followed by R0 resection with non-pCR, adjuvant nivolumab was well-tolerated. However, this retrospective study was a small population, the further investigation is needed to evaluate long-term efficacy.
Reference Key
openalex_W7203970982 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Ryuichi Morita, Shun Yamamoto, Hiroshi Imazeki, Hideaki Takahashi, Yoshitaka Honma, Daisuke Kurita, Koshiro Ishiyama, Tairo Kashihara, Hiroyuki Daiko, Yasuyuki Seto, Ken Kato
Are you one of these authors? Claim your profile
Journal diseases of the esophagus : official journal of the international society for diseases of the esophagus
Year 2026
DOI
10.1093/dote/doag077.232
URL
https://doi.org/10.1093/dote/doag077.232
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.